Semaglutide vs tirzepatide comparison Canadian research peptides Durham Peptides "Semaglutide vs tirzepatide" is one of the most-searched comparison queries in the Canadian research peptide market, and for good reason. The two compounds sit at the center of the incretin peptide class — the research area that has produced more clinical trial data than any other peptide category in the past decade. For Canadian researchers entering the metabolic peptide space, understanding the

Triple agonist peptides retatrutide GLP-3 research Durham Peptides Canada Few peptide categories have moved as fast as triple agonist metabolic peptides. In less than a decade, the field has progressed from single-receptor compounds (semaglutide) to dual-receptor compounds (tirzepatide) to the first triple-receptor agonist — retatrutide — currently in advanced clinical trials. Each generation has generated more research attention than the last, and the terminology has evolved